Solid biosciences provides fourth quarter and full-year 2022 business update and financial results

- completed the acquisition of aavantibio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; closed concurrent $75 million private placement -
SLDB Ratings Summary
SLDB Quant Ranking